Navigation Links
Shire Continues to Deliver Excellent Growth From Core Products
Date:10/30/2009

nding to this subpoena. - On October 19, 2009 Teva Pharmaceuticals USA, Inc. ("Teva") filed suit against Shire claiming that Shire is in breach of its supply contract for the authorized generic version of ADDERALL XR. Shire has been supplying Teva with authorized generic ADDERALL XR since April 1, 2009. Shire's ability to supply this product, however, is limited by quota restrictions that the US Drug Enforcement Administration places on amphetamine, which is the product's active ingredient.

2009 OUTLOOK

We are reiterating our previously announced guidance framework for Non GAAP diluted earnings per ADS for 2009, which remains unchanged from that provided in our Q3 2008 earnings release. At that time, and in subsequent earnings releases, we provided details of the effect of changes in foreign exchange rates on the earnings guidance. Specifically, our plans for 2009, supporting Non GAAP diluted earnings per ADS for 2009 in the range of $3.00 to $3.40, were based on average actual foreign exchange rates (EUR1:$1.52, GBP1:$1.95) for the ten months to October 2008. During the first three quarters of 2009 we have already achieved Non GAAP diluted earnings per ADS of $2.38.

We identified that each 10c movement in the EUR:$ and GBP:$ exchange rates impacts Shire's Non GAAP diluted earnings per ADS by $0.10 and $0.01 respectively. Based on the following exchange rate scenarios, which are not forecasts, the impact on our base guidance would be:

                                      Euro fx    GBP fx    Non GAAP diluted
                                       rate        rate    earnings per ADS
                                                               range(1)

    Base guidance                      $1.52      $1.95     $3.00 to $3.40
    As advised at Q2 2009              $1.37      $1.56     $2.80 to $3.20
    At average rate for nine months
    to September 2009 &
'/>"/>
SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related medicine technology :

1. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
2. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
3. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
4. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
5. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
6. Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
7. Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
8. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
9. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
10. Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
11. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... HILL, N.C. , Sept. 19, 2014 ... to Best Practices, LLC with three issues he wanted ... , The use of external personnel (especially for secondary ... headcount in the face of increased workload , ... and better knowledge management , How to implement ...
(Date:9/19/2014)... 2014 /PRNewswire-iReach/ -- Market Research Report on ... is a professional and in-depth market survey ... The report firstly reviews the basic information ... and manufacturing technology. The report then explores ... Hydrochloride listing their product specification, capacity, Production ...
(Date:9/19/2014)... 2014 Kiromic, LLC, a Lubbock ... Hance , the former chancellor of Texas Tech University, to ... in July 2014, after raising $1.2 billion for the university. ... Hance , the most successful chancellor in the history of ... as an investor, but also as our new vice chairman ...
Breaking Medicine Technology:In Era of Competing Needs, Market Research Groups Under Pressure to Utilize Automation and External Staffing 2Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 2Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 3Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 4Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 5Former Texas Tech Chancellor Named New Vice Chairman of the Board of Kiromic, LLC 2
... Therapeutics (NYSE Amex: CXM ) today provided an ... Pharmaceuticals, business assets in connection with a proposed asset purchase ... on June 27, 2011, the completion of such an asset ... of the bankruptcy court.  In an effort to expedite the ...
... Corporation,s (NYSE: BSX ) Board of Directors ... up to $1.0 billion of its common stock and ... existing share repurchase program. "This repurchase program ... long-term business prospects, earnings growth potential and our ability ...
Cached Medicine Technology:Cardium Reports on Transdel Transaction 2Cardium Reports on Transdel Transaction 3Cardium Reports on Transdel Transaction 4Boston Scientific Announces $1.0B Share Repurchase Program 2Boston Scientific Announces $1.0B Share Repurchase Program 3
(Date:9/20/2014)... Dallas, TX (PRWEB) September 20, 2014 ... – Forecast and Market Analysis to 2023?. The ... past decade, as it has become saturated with ... (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting ... been facing increasing generic competition. However, the launch ...
(Date:9/20/2014)... Recently, Best Cheap Hosting USA ... its new website. The new site provides the ... products for customers. Here, people can find a ... decision. Also, it has recommended some excellent web ... of the great web hosting suppliers, InMotion ( ...
(Date:9/20/2014)... 20, 2014 "As a nurse, patients always ... said an inventor from Tamaqua, Pa. "The reason that they ... backs of their chairs. My invention enables them to check ... Oxygen Sensor to make it easier to monitor the contents ... knows when the tank is low. It allows changeovers to ...
(Date:9/20/2014)... (PRWEB) September 20, 2014 Earlier this week, ... customers may have had their credit card information pilfered by ... spawning a slew of headline articles like this one ... the only eye opening numbers. , “Most people tend ... almost like it’s a way to score a game,” says ...
(Date:9/20/2014)... Final Cut Pro X Plugin ... the Information theme for FCPX filmmakers. , “Fun, cool, and ... Information theme,” says Christina Austin, CEO of Pixel Film Studios. ... , Information features easy to use controls that give the ... Change the background color, color of each circle outline, the ...
Breaking Medicine News(10 mins):Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 2Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 3Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 4Health News:Best Cheap Hosting USA Launches Its New Website And Recommends InMotion To Worldwide People 2Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 2Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 3Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 4Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 5Health News:Today Pixel Film Studios Announced the Release of the Information Theme for Final Cut Pro X 2
... in Higher Education (AGHE), the educational branch of ... its 35th Annual Meeting and Educational Leadership Conference ... Plaza Hotel-Riverwalk in San Antonio, TX. This conference ... aging to present their work and share ideas about ...
... without spending,a lot of cash? It,s true. In fact, you ... boosting your health, lowering your stress level and,cleaning out your ... Hilling has spent more than 15 years researching,and designing products ... With the ten thrifty tips, this host of "Skin Health ...
... RED BANK, New Jersey, BRUSSELS and MELBOURNE, January 30, ... over a century of expertise, the global leader in ... the web. The,new http://www.ansell.com website is now ... new Investor Centre. , The ...
... Studies Initiated in Other Oncology SettingsLONDON and COPENHAGEN, ... A/S (OMX: GEN) announced today the submission of ... Food and Drug Administration (FDA) for Arzerra(TM) ... leukemia (CLL) is resistant (refractory) to previous therapies. ...
... and LISLE, Ill., Jan. 30 SpineMark Corporation,a ... and,physicians to develop Spine Centers of Excellence, has ... high quality spinal care at,cost effective rates through ... Management solution, the Healthplace Surgery Benefit(TM). As ...
... Management Group, Inc. (Phyhealth) (Pink Sheets: PHYH), ... partnership with physicians and manager of Physhield Insurance ... the following letter to its shareholders:Dear Phyhealth Shareholder:We ... and a new administration in Washington. Healthcare ...
Cached Medicine News:Health News:Teaching about financial crisis among Gerontology Meeting's highlights 2Health News:Ten Thrifty Tips for Radiant Skin 2Health News:Ten Thrifty Tips for Radiant Skin 3Health News:Ansell Limited Launching a New Global Website 2Health News:GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer 2Health News:GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer 3Health News:GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer 4Health News:GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer 5Health News:GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer 6Health News:GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer 7Health News:GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer 8Health News:SpineMark Partners With Healthplace America to Offer Access to Top Quality Spinal Care 2Health News:SpineMark Partners With Healthplace America to Offer Access to Top Quality Spinal Care 3Health News:SpineMark Partners With Healthplace America to Offer Access to Top Quality Spinal Care 4Health News:Phyhealth Provides Update to Shareholders 2Health News:Phyhealth Provides Update to Shareholders 3Health News:Phyhealth Provides Update to Shareholders 4
Knife rasp for shoulder arthroscopy....
Loop handle knot pusher...
Shoulder rasp...
Arthrex has the most extensive offering of arthroscopic suture passing instruments,available anywhere in the world. We have speci? cally designed the function of our,instruments to work hand in hand ...
Medicine Products: